Ignite Creation Date:
2024-05-06 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05727163
Status:
RECRUITING
Last Update Posted:
2024-03-04
First Post:
2022-10-24
Brief Title:
FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Organization Data
Organization:
Sun Yat-sen University
Class:
OTHER
Study ID:
New Triumph
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Sun Yat-sen University
Lead Sponsor Class:
OTHER
Responsible Party:
Yuhong Li
Responsible Party Title:
Clinical Professor
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Sun Yat-sen University
Old Name:
None
Old Organization:
None